GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Replek AD (XMAE:REPL) » Definitions » Cyclically Adjusted PB Ratio

Replek AD (XMAE:REPL) Cyclically Adjusted PB Ratio : (As of Jun. 03, 2025)


View and export this data going back to . Start your Free Trial

What is Replek AD Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Replek AD Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Replek AD's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Replek AD Cyclically Adjusted PB Ratio Chart

Replek AD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.30 1.36 2.32

Replek AD Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.66 - 2.32 -

Competitive Comparison of Replek AD's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Replek AD's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Replek AD's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Replek AD's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Replek AD's Cyclically Adjusted PB Ratio falls into.


;
;

Replek AD Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Replek AD's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Replek AD's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0/134.9266*134.9266
=0.000

Current CPI (Mar. 2025) = 134.9266.

Replek AD Quarterly Data

Book Value per Share CPI Adj_Book
201503 0.000 99.621 0.000
201506 5,171.788 100.684 6,930.719
201509 0.000 100.392 0.000
201512 5,406.216 99.792 7,309.598
201603 0.000 100.470 0.000
201606 5,268.510 101.688 6,990.613
201609 0.000 101.861 0.000
201612 5,552.151 101.863 7,354.339
201703 0.000 102.862 0.000
201706 4,877.367 103.349 6,367.608
201709 0.000 104.136 0.000
201712 5,708.981 104.011 7,405.877
201803 0.000 105.290 0.000
201806 5,476.645 106.317 6,950.408
201809 0.000 106.507 0.000
201903 0.000 107.251 0.000
201906 5,368.768 108.070 6,702.998
201909 0.000 108.329 0.000
201912 5,684.104 108.420 7,073.751
202003 0.000 108.902 0.000
202006 5,526.838 108.767 6,856.081
202009 0.000 109.815 0.000
202012 5,899.104 109.897 7,242.668
202103 0.000 111.754 0.000
202106 6,056.459 114.631 7,128.740
202109 0.000 115.734 0.000
202112 6,025.162 117.630 6,911.146
202203 0.000 121.301 0.000
202206 6,188.973 125.017 6,679.559
202209 0.000 125.227 0.000
202212 5,922.143 125.222 6,381.114
202303 0.000 127.348 0.000
202306 5,962.409 128.729 6,249.481
202309 0.000 129.860 0.000
202312 8,552.722 129.419 8,916.667
202403 0.000 131.776 0.000
202406 8,540.649 132.554 8,693.532
202409 0.000 133.029 0.000
202412 9,142.425 133.157 9,263.917
202503 0.000 134.927 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Replek AD  (XMAE:REPL) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Replek AD Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Replek AD's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Replek AD Business Description

Industry
Traded in Other Exchanges
N/A
Address
Kozle 188, Skopje, MKD
Replek AD is engaged in the development, design and production of generic medicines. The company develops drugs in different pharmaceutical therapeutic categories including anti-platelet, lipid-lowering, atypical antipsychotic, anti-infective, among others. It manufactures drugs in different forms including tablets, capsules, oral solutions, creams and ointments. Its product portfolio consists of Clopidogrel, Atorvastatin, Simvastatin, risperidone, Clarythromycin, Ciprofloxacin, Meloksikam, Risperidon, terazosin, among others. Replek also offers cannabis oil products, food supplements and cosmetics.